# Trade Mark Journal No.2026/022 29 May 2026

## UK00004388106 15 May 2026 (5,42,44)

PRECEDE BIO INSIGHT

International priority date claimed: 20 January 2026 (United States of America) (99603645)

Class 5
  Diagnostic assays and reagents for clinical and medical use, namely, for the testing of body fluids; diagnostic chemical, biochemical and biological preparations for medical purposes, namely, for treating and preventing cancers and other clinical pathologies; diagnostic test kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, cancers.
Class 42
  Software as a service (SAAS) services featuring software for inputting, accessing, viewing, processing and analyzing medical data; data as a service (DAAS) services featuring non-downloadable software for the provision of data, namely, for inputting, accessing, viewing, processing and analyzing medical data; computer services, namely, providing data as a service (DaaS) services featuring non-downloadable software for analyzing and managing data for purposes of drug development and discovery; computer services, namely, the provision of data as a service (DaaS) in the pharmaceuticals and healthcare fields for analyzing medical research data information in relation to pharmaceutical drug discovery and drug development; pharmaceutical research and development; pharmaceutical drug development and drug discovery services; medical research and scientific research; providing medical and scientific research information in the field of pharmaceuticals research and development of technology in the field of pharmaceuticals; biomedical research services; product development in the field of pharmaceuticals, namely, the development of preclinical and therapeutic product.
Class 44
  Medical testing and diagnostic services; clinical pathology services, namely, medical pathology services; medical analysis services for diagnostic and treatment purposes relating to the treatment of persons in the nature of genomic and epigenomic profiling of human biological samples; medical testing for diagnostic or treatment purposes in the field of pathology relating to the treatment of persons; medical diagnostic testing, monitoring and reporting services; diagnostics services, namely, the recommendation of medical treatment for identified disease states.

Precede Biosciences, Inc.

Representative: Groom Wilkes & Wright LLP